Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 10/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1467635 | 0.89 | SMN1; SMN2 (0.49) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL13296433 | 0.83 | ACHE (0.66) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL24131321 | 0.82 | LMNA (0.49) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL10119353 | 0.81 | LMNA (0.51) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL18075914 | 0.81 | LMNA (0.51) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL8193146 | 0.81 | ACHE (0.53) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL3792109 | 0.81 | LMNA (0.51) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL10141268 | 0.81 | ACHE (0.58) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL24131327 | 0.81 | LMNA (0.48) | LMNAALDH1A1SMN1; SMN2ALOX15ACHE | |
| SCHEMBL1468073 | 0.80 | SMN1; SMN2 (0.51) | LMNAALDH1A1SMN1; SMN2ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6329400-B1 | INHIBITION OR ANTAGONISM OF MATRIX METALLOPROTEASES, AND/OR TUMOR NECROSIS FACTOR-ALPHA; EXTRACELLULAR MATRIX DEGRADATION, INHIBITION OF SHEDDING OF CELL SURFACE PROTEIN ECTODOMAINS AND CD23 PROTEOLYSIS | GLAXO WELLCOME INC. | 2001-12-11 | — | — | US | disclosed |